ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016
Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02776111 (The Use of Microfluidics and Transcriptomics to Implement Precision Medicine in Post Solid Organ Transplant Patients), which is not on this map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Use of Microfluidics and Transcriptomics to Implement Precision Medicine in Post Solid Organ Transplant Patients
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Health Disparities in Kidney Transplantation for African Americans.American journal of nephrology · 2017Pooled it
- A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement.Clinical pharmacokinetics · 2020Trial
- Severe rise in tacrolimus levels following blood orange and grapefruit juice intake in a kidney transplant recipient: a case report.Journal of medical case reports · 2026Article
- Identification of Microbiome Associations with Tacrolimus Pharmacokinetics in Adult Hematopoietic Cell Transplantation Using Population Pharmacokinetic and Machine Learning.Pharmaceutical research · 2026Observational
- Transforming Advanced Heart Failure Programs: Addressing Institutional and Systemic Drivers of Racial and Ethnic Disparities in Care.Circulation. Heart failure · 2026Review
- Lower Dose-Normalized Tacrolimus Exposure in CYP3A5*6 vs. *3 Loss-of-Function Allele Carriers: A Longitudinal Retrospective Real-World Study in Kidney Transplant Recipients.Clinical pharmacology and therapeutics · 2026Article
- Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients.The pharmacogenomics journal · 2026Article
- Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients.Clinical and translational science · 2025Article
- Hidden in Plain Sight: Low Tacrolimus Metabolism Doubles Kidney Transplant Failure and Drives Infection Related Mortality.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Alleles ofPeerJ · 2025Article
- Impact of High Tacrolimus Exposure on Graft Function and Development of a Prediction Model in Kidney Transplant Recipients: A Single-Center Retrospective Cohort Study.Drug design, development and therapy · 2025Article
- Steroid-tacrolimus drug-drug interaction and the effect of CYP3A genotypes.British journal of clinical pharmacology · 2024Article
- Elucidating the nexus between onco-immunology and kidney transplantation: An insight from precision medicine perspective.Heliyon · 2024Review
- Exploratory associations of tacrolimus exposure and clinical outcomes after lung transplantation: A retrospective, single center experience.European journal of clinical pharmacology · 2024Observational
- Implementing community-engaged pharmacogenomics in Indigenous communities.Nature communications · 2024Article
- Sociodemographic Disparities in Adults with Kidney Failure: A Meta-Analysis.Diseases (Basel, Switzerland) · 2024Review
- Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review.Pharmacogenomics · 2024Review
- Polygenic risk score for acute rejection based on donor-recipient non-HLA genotype mismatch.PloS one · 2024Article
- Novel Aspects of Immunogenetics and Post-Transplant Events in Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers.Clinical transplantation · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
Abstract
We previously reported that tacrolimus (TAC) trough blood concentrations for African American (AA) kidney allograft recipients were lower than those observed in white patients. Subtherapeutic TAC troughs may be associated with acute rejection (AR) and AR-associated allograft failure. This variation in TAC troughs is due, in part, to differences in the frequency of the cytochrome P450 CYP3A5*3 allele (rs776746, expresses nonfunctional enzyme) between white and AA recipients; however, even after accounting for this variant, variability in AA-associated troughs is significant. We conducted a genomewide association study of TAC troughs in AA kidney allograft recipients to search for additional genetic variation. We identified two additional CYP3A5 variants in AA recipients independently associated with TAC troughs: CYP3A5*6 (rs10264272) and CYP3A5*7 (rs41303343). All three variants and clinical factors account for 53.9% of the observed variance in troughs, with 19.8% of the variance coming from demographic and clinical factors including recipient age, glomerular filtration rate, anticytomegalovirus drug use, simultaneous pancreas-kidney transplant and antibody induction. There was no evidence of common genetic variants in AA recipients significantly influencing TAC troughs aside from the CYP3A gene. These results reveal that additional and possibly rare functional variants exist that account for the additional variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.